A membrane separator comprising a membrane is used to separate various streams in processes for separating aromatic hydrocarbons from non-aromatic hydrocarbons. Such streams can be a lean-solvent stream, a rich-solvent stream, or a hydrocarbon stream comprising both aromatic and non- aromatic hydrocarbons. The membrane separator is advantageously used in combination with an extraction sub-system including a liquid—liquid distillation column and/or an extraction distillation column.

A process for endothermic dehydrogenation including contacting a catalyst material in a moving bed reactor having at least one reaction zone, the moving bed reactor comprising a heat exchanger containing a heating medium, wherein the catalyst material and the heating medium do not contact one another, and wherein at least 50% of the delta enthalpy of the at least one reaction zone is provided by the heat exchanger; and contacting a feedstock comprising hydrocarbons with the catalyst material in the at least one reaction zone of the moving bed reactor under reaction conditions to convert at least a portion of the hydrocarbons to a first effluent comprising a product comprising alkenes, alkynes, cyclic hydrocarbons, and/or aromatics.

A process for endothermic dehydrogenation including contacting a catalyst material in a moving bed reactor having at least one reaction zone, the moving bed reactor comprising a heat exchanger containing a heating medium, wherein the catalyst material and the heating medium do not contact one another, and wherein at least 50% of the delta enthalpy of the at least one reaction zone is provided by the heat exchanger; and contacting a feedstock comprising hydrocarbons with the catalyst material in the at least one reaction zone of the moving bed reactor under reaction conditions to convert at least a portion of the hydrocarbons to a first effluent comprising a product comprising alkenes, alkynes, cyclic hydrocarbons, and/or aromatics.

The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.

The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.

The disclosures herein provide compounds of formula I ##STR00001##
or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

The disclosures herein provide compounds of formula I ##STR00001##
or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

The present disclosure relates to methods for treating an ANCA associated vasculitis, for example, granulomatosis with polyangiitis (GPA), with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof,

##STR00001##

that inhibit dipeptidyl peptidase 1 (DPP1) activity. In one embodiment, the compound of Formula (I) is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (INS1007).

The present disclosure relates to methods for treating an ANCA associated vasculitis, for example, granulomatosis with polyangiitis (GPA), with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof,

##STR00001##

that inhibit dipeptidyl peptidase 1 (DPP1) activity. In one embodiment, the compound of Formula (I) is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (INS1007).

Provided are, for example, (i) a drug that reacts with acrolein and (ii) a use thereof. A drug that reacts with acrolein in accordance with an embodiment of the present invention contains a compound having a chemical structure represented by Formula (1):

##STR00001##